{"name":"PTC Therapeutics","slug":"ptc","ticker":"PTCT","exchange":"NASDAQ","domain":"ptcbio.com","description":"PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.","hq":"South Plainfield, NJ","founded":0,"employees":"991","ceo":"Matthew Klein","sector":"Rare Disease / Gene Therapy / Neuroscience","stockPrice":71.37,"stockChange":1.79,"stockChangePercent":2.57,"marketCap":"$5.9B","metrics":{"revenue":264734000,"revenueGrowth":-22.7,"grossMargin":71,"rdSpend":455249000,"netIncome":682644000,"cash":1945371008,"dividendYield":0,"peRatio":8.3,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Translarna patent cliff ($1.3B at risk)","drug":"Translarna","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"PTC518","genericName":"PTC518","slug":"ptc518","indication":"Other","status":"phase_2"},{"name":"Translarna","genericName":"ATALUREN","slug":"ataluren","indication":"Duchenne muscular dystrophy","status":"marketed"},{"name":"CNSA-001","genericName":"CNSA-001","slug":"cnsa-001","indication":"Spinal Muscular Atrophy","status":"phase_2"},{"name":"Upstaza","genericName":"ELADOCAGENE EXUPARVOVEC","slug":"eladocagene-exuparvovec","indication":"Deficiency of aromatic-L-amino-acid decarboxylase","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ataluren (PTC124®)","genericName":"Ataluren (PTC124®)","slug":"ataluren-ptc124","indication":"Duchenne muscular dystrophy (DMD) with nonsense mutations","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"PTC923","genericName":"PTC923","slug":"ptc923","indication":"Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)","status":"phase_3"}]}],"pipeline":[{"name":"PTC518","genericName":"PTC518","slug":"ptc518","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Translarna","genericName":"ATALUREN","slug":"ataluren","phase":"marketed","mechanism":"Flavin reductase (NADPH)","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"Ataluren (PTC124®)","genericName":"Ataluren (PTC124®)","slug":"ataluren-ptc124","phase":"phase_3","mechanism":"Ataluren allows ribosomes to read through premature stop codons (nonsense mutations) and produce full-length, functional proteins.","indications":["Duchenne muscular dystrophy (DMD) with nonsense mutations","Cystic fibrosis with nonsense mutations","Hemophilia B Leyden"],"catalyst":""},{"name":"CNSA-001","genericName":"CNSA-001","slug":"cnsa-001","phase":"phase_2","mechanism":"CNSA-001 is a small molecule that targets the underlying cause of a specific disease.","indications":["Spinal Muscular Atrophy"],"catalyst":""},{"name":"PTC923","genericName":"PTC923","slug":"ptc923","phase":"phase_3","mechanism":"PTC923 is a small-molecule inhibitor of pyruvate dehydrogenase kinase (PDK) that restores pyruvate dehydrogenase (PDH) activity to improve mitochondrial energy metabolism.","indications":["Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)","Other mitochondrial or metabolic disorders"],"catalyst":""},{"name":"Upstaza","genericName":"ELADOCAGENE EXUPARVOVEC","slug":"eladocagene-exuparvovec","phase":"marketed","mechanism":"Upstaza works by replacing the deficient enzyme aromatic-L-amino-acid decarboxylase.","indications":["Deficiency of aromatic-L-amino-acid decarboxylase"],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"PTC Therapeutics Announces FDA Approval of Translarna for the Treatment of Duchenne Muscular Dystrophy","summary":"The FDA approved Translarna (ataluren) for the treatment of Duchenne muscular dystrophy in patients aged 5 and older with nonsense mutations in the dystrophin gene.","drugName":"Translarna","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"PTC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"PTC Therapeutics reported its financial results for the fourth quarter and full year 2021, including revenue of $143.8 million and a net loss of $143.8 million.","drugName":"","sentiment":"neutral"},{"date":"2021-12-13","type":"deal","headline":"PTC Therapeutics Announces Collaboration with the Cystinosis Research Foundation","summary":"PTC Therapeutics announced a collaboration with the Cystinosis Research Foundation to advance the development of treatments for cystinosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance? - simplywall.st","headline":"Is It Time To Reassess PTC Therapeutics (PTCT) After Mixed Multi Year Share Performance?","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOaUVPdTYyLWNjUkJSUVJRQnNwVlliUFVHSXNuSkRPMTNTUENzRWI0aU4yZzZhaVA1cm5pQVFVVHMzc1BXLW51RUVRVjFhWS1zN1JoNHRuTEtCUWUzNkM5WWZ6RkdvQzFPTHgtWUNnY0toRk9LNTRpRUY1RHpkTVJZV25TTmNkZGpXdWdRN2JfTkliME5HVTAwb1d6VGNRZ2d2dUg2VDJWamZQVWxSZ0xnazR2SlM1ZVVJa3paUkU2c2I2aXdScnpUbXpwQlhjT3pfX29ScDVyQ3hMclZueDJ6ai1VTHBVNVdDekhHN1RUeVY?oc=5","date":"2026-02-28","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVHRieWRIQ09tN1k1d3hIWG01V0RaM3U1aGVZVXZNemx0djhJMGtXOTNSd3FhdE1iWGhacW5ubGJzc05Lek50YWs2TklLZGhHZm1FeVpaSm1FdU1aMktJNkRRU3ZJNEp6M2dUbC1YbkhRQXFRR0l2OEpmanlUcDRsRWUtSEFiOWRoWE9vd2xiWEtCdXI2R1Zr?oc=5","date":"2026-02-23","type":"pipeline","source":"Seeking Alpha","summary":"PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT) - Seeking Alpha","headline":"PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNd1J6T25LMVJIeERaQm5ZMWdTeVNweE5DUFJmXzB1dTlwaVJMSkt4Mk9xemZPVnFuYWQ5SzBQdmhmVEpTcmxMQUhOQk9mSG5uMUxLR2ZpNm5jZXV1SjRhRV9MeXFKM28wT1FVSWhkYUQ5NmllLXNNWmRtYXFHcElSUEtMRUluOVdVb0NfSFhn?oc=5","date":"2026-02-13","type":"pipeline","source":"The Pharma Letter","summary":"PTC Therapeutics withdraws Translarna NDA - The Pharma Letter","headline":"PTC Therapeutics withdraws Translarna NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdjNLTGFLZF9mU3Z1VzItWUQ1YlJIX2hLWnBfNnBDbWlNYjBDWk4tVV81MU9ZWUhYSmUtRmI4ak1sNjU0MkFSVi11NWFjcHlXaS0zeFBFTmlmYTJjSG9ORktjZkx6NGw2NHptNW5jTmw0aVhIbVFkMjRtVjlIQnBMamdLd3RSaDJPZ1ZKRjdWcGhwMmNpX0xNSXRmc3MtV0V3Mzl2emNqaUdyUQ?oc=5","date":"2026-02-13","type":"regulatory","source":"MedCity News","summary":"PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug - MedCity News","headline":"PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNb1l4ZFByYlkxbWZPd2dnZ1YyaVVRZ3hyU2ZjWW5ZLVE4T25FNnFRdTJkSnBubjR3alFYRFJQS2dOelAwUWdjSnZzYXJ1ekV0Y1V5WU42M1hmVkhIZGlRRG9uU2o4R0cwdDFZR3hXZ3RzOXZQaXF6N1RTU3g3a1JqLW92Yw?oc=5","date":"2025-08-29","type":"regulatory","source":"Yahoo Finance","summary":"PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia - Yahoo Finance","headline":"PTC Therapeutics, Inc. (PTCT) Faces FDA Setback on Vatiquinone for Friedreich’s Ataxia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOLU1TYkxUQ3o3Rmpfd1Z5bHJ2SDFMc0lZcUlNbHNiVHV6VlBVQ2FzS2tnYUgybjFxaXc0M05maEVORUFPOEhwRV8yWkFOYmNuZmNjUkhxR2pldGwxanNLTXRmTWVuT3QtZnpEZG55OEFZanhDdTg3LVZMY0psdV9Kd1BBOFJ2Q1F2QTVHNFBqRkh4alpGSHhZLUcwM0ZUOXRxREdjTHUtRE5tZGNVaFV2R2lna0xqTXZ3VC1uSQ?oc=5","date":"2025-08-19","type":"pipeline","source":"Mintz","summary":"Mintz Advises Former Shareholders of Censa Pharmaceuticals in the Sale of its Earnout Royalties Rights back to PTC Therapeutics - Mintz","headline":"Mintz Advises Former Shareholders of Censa Pharmaceuticals in the Sale of its Earnout Royalties Rights back to PTC Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNSUtUbkZqb3B3REhqZjVHR3cwQm9Ka2kzTUxBSURIUWlFTHYtSVJCZHcyQUpKbGxldV9aVXN4YXh0QWpIc0NsX3NQSWkxaThrOXozMzhJbnBmYkczN2JWOTBIT0ltT1BMbkxnY2NiVU1Ca1owY0FWQVAyeUJDVWRaZGdCMlUzNktJLV96c0xZNDA5c0xPdHJ3ZVJIVk5hUzQ4Xzl5OTdPNGdfUjR5clZVYkpRVG41aGhhZWVhclZBTUdBVms?oc=5","date":"2025-07-29","type":"regulatory","source":"Sahm","summary":"Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics - Sahm","headline":"Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNaFRRZ2pfRDNDcVdHSjZuVDVaYkRNQVg4VDRvQnZ0bEN0aHdlbENCSW9Vdm9uLWRPcDVVdVl5RGdxMzRoUUhORXBvanVlXzdoMi12S1VtM1MwUXQwbUQ0Y0w4WTJDZTF4eG5QZzBCRlVGeUZQci0wMjlDU09QdFFwVl84WFkwdjdlQjR0b1Y2NXR6bUVQSl9raGstRnNaMlNMdm4xaW9EMk5fOWNpcDc2MFVXOHR3WFFuMXMwZ2IwZjgwSmQ4amc4?oc=5","date":"2025-07-28","type":"regulatory","source":"Reuters","summary":"US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters","headline":"US FDA approves PTC Therapeutics' metabolic disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQY1liVXFWLWFJbmFHeDQ2blQ4OWdTTW1Oamc3ckQydE9pSFd6ZmxKNGNGRGhZcldTbkUyMWQyX0tkUXd2REpZNUxHLVI4M19CZmlxcDZ1T1VsMEIzLXBId21FSTJmampnenhSMjJ5YkZaU0cyYUhxa3c3UmVXNWtlN0VITmdtSHFNTnRiQnNn?oc=5","date":"2025-06-25","type":"regulatory","source":"The Pharma Letter","summary":"EC approves PTC Thera’s Sephience for PKU - The Pharma Letter","headline":"EC approves PTC Thera’s Sephience for PKU","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9BNFZyb1F0bjFLeksyZlhEeHlMeTRhLU85VTY2bG9iWGJFT0J5bUZIOGJjazVXQnNuMEtIMVpfaTZXNW9JMGFIejk2WFB6a2FKQldZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PTCT Stock Price, News & Analysis - Stock Titan","headline":"PTCT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQa2JlbXlmRTc2VjNqYmRYVXpiMEkxWF9ReldidUNIM25nSmt6Ym43VlFSVnpjbWdYb29QNkw1SG0tSDRWdzgwVmV3VnZIeTNtQ3Bwa3U3M09YRy1HMEVLU1Q4dHdTcnNTTFNGZTh6OEw0RWlSOXFwdkc1N2pZRkZjZGhGVWlUTzhvN1QtaFhEZDVqa2RSTFp5QlBfTjBnbDJKY0N0MFM2X0NCTHg3ZHZVWFhMUjlNVEFiYjl4XzJubUNNWElGVXlFaFJYTjZmdjhvSmhYRGJyblZyTHly?oc=5","date":"2023-10-25","type":"pipeline","source":"WilmerHale","summary":"WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma - WilmerHale","headline":"WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma","sentiment":"neutral"}],"patents":[{"drugName":"Translarna","drugSlug":"ataluren","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1300000000}],"drugCount":6,"phaseCounts":{"phase_2":2,"marketed":2,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sarepta Therapeutics","Biogen","Pfizer"],"therapeuticFocus":["Rare Disease","Gene Therapy","Neuroscience"],"financials":{"source":"sec_edgar","revenue":264734000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":264734000,"period":"2018-12-31"},{"value":194392000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":455249000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":682644000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2898767000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":71.37,"previousClose":69.58,"fiftyTwoWeekHigh":87.5,"fiftyTwoWeekLow":35.95,"fiftyTwoWeekRange":"35.95 - 87.5","fiftyDayAverage":69.2,"twoHundredDayAverage":64.53,"beta":0.55,"enterpriseValue":6464871936,"forwardPE":29.4,"priceToBook":-28.32,"priceToSales":3.41,"enterpriseToRevenue":3.74,"enterpriseToEbitda":7.22,"pegRatio":0,"ebitda":895323008,"ebitdaMargin":51.7,"freeCashflow":211756752,"operatingCashflow":711196032,"totalDebt":2707064064,"debtToEquity":0,"currentRatio":2.35,"returnOnAssets":23.3,"returnOnEquity":0,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":86.5,"targetHighPrice":124,"targetLowPrice":60,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.4,"institutionHeldPercent":113.4,"sharesOutstanding":82774730,"floatShares":72935298,"sharesShort":8847565,"shortRatio":7.23,"shortPercentOfFloat":10.7,"epsTrailing":8.58,"epsForward":2.43,"revenuePerShare":21.76,"bookValue":-2.52,"officers":[{"age":52,"name":"Dr. Matthew B. Klein F.A.C.S., M.D., M.S.","title":"CEO & Director"},{"age":79,"name":"Dr. Allan Steven Jacobson Ph.D.","title":"Co-Founder & Independent Director"},{"age":39,"name":"Mr. Pierre  Gravier M.S.","title":"Chief Financial Officer"},{"age":58,"name":"Dr. Neil  Almstead Ph.D.","title":"Chief Technical Operations Officer"},{"age":64,"name":"Mr. Eric  Pauwels","title":"Chief Business Officer"},{"age":57,"name":"Dr. Lee Scott Golden M.D., Ph.D.","title":"Executive VP & Chief Medical Officer"},{"age":46,"name":"Ms. Christine  Utter CPA","title":"Senior VP, Chief Accounting Officer & Head of People Services"},{"age":null,"name":"Ms. Linda Montella Carter","title":"Senior VP & Chief Information Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ptcbio.com","phone":"908 222 7000"}}